Denali Therapeutics Financials
| DNLI Stock | USD 23.58 0.17 0.73% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Debt Equity Ratio | 0.0879 | 0.0583 |
|
| |||||
| Current Ratio | 15.07 | 15.69 |
|
|
Investors should never underestimate Denali Therapeutics' ability to pay suppliers on time, ensure interest payments are not accumulating, and correctly time where and how to reinvest extra cash. Individual investors need to monitor Denali Therapeutics' cash flow, debt, and profitability to make informed and accurate decisions about investing in Denali Therapeutics.
Net Income |
|
Denali | Select Account or Indicator |
Understanding current and past Denali Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Denali Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Denali Therapeutics' assets may result in an increase in income on the income statement.
Denali Therapeutics Stock Summary
Denali Therapeutics competes with Stoke Therapeutics, Black Diamond, 4D Molecular, Ascendis Pharma, and Apellis Pharmaceuticals. Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Denali Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 5 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US24823R1059 |
| CUSIP | 24823R105 |
| Location | California; U.S.A |
| Business Address | 161 Oyster Point |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.denalitherapeutics.com |
| Phone | 650 866 8548 |
| Currency | USD - US Dollar |
Denali Therapeutics Key Financial Ratios
| Return On Equity | -0.35 | ||||
| Price To Sales | 3,339 X | ||||
| Revenue | 330.53 M | ||||
| Gross Profit | (412.36 M) | ||||
| EBITDA | (179.97 M) |
Denali Therapeutics Key Balance Sheet Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Total Assets | 1.6B | 1.4B | 1.5B | 1.2B | 1.3B | 932.8M | |
| Other Current Liab | 42.5M | 47.7M | 63.8M | 61.2M | 70.4M | 73.9M | |
| Other Liab | 44.1M | 317.9M | 5.1M | 858K | 986.7K | 937.4K | |
| Net Tangible Assets | 394.9M | 1.2B | 962.3M | 1.0B | 1.2B | 612.3M | |
| Net Debt | (443.0M) | (234.9M) | (157.7M) | (74.9M) | (67.4M) | (70.7M) | |
| Retained Earnings | (354.4M) | (645.0M) | (971.0M) | (1.1B) | (1.0B) | (954.4M) | |
| Accounts Payable | 1.1M | 4.8M | 2.8M | 9.5M | 10.9M | 11.5M | |
| Cash | 507.1M | 293.5M | 218.0M | 127.1M | 146.2M | 194.5M | |
| Other Assets | 2.5M | 11.9M | 13.4M | 1.0 | 1.15 | 1.09 | |
| Capital Surpluse | 774.2M | 818.8M | 1.5B | 1.6B | 1.8B | 1.9B | |
| Other Current Assets | 20.3M | 30.6M | 26.8M | 26.2M | 30.1M | 17.6M | |
| Total Liab | 453.7M | 441.9M | 417.8M | 123.0M | 141.4M | 220.0M | |
| Total Current Assets | 1.5B | 897.2M | 1.4B | 1.1B | 1.2B | 778.0M | |
| Common Stock | 1.5M | 1.5M | 1.7M | 1.7M | 2.0M | 1.6M | |
| Net Invested Capital | 1.2B | 962.3M | 1.0B | 1.0B | 1.2B | 879.0M | |
| Net Working Capital | 1.4B | 519.0M | 1.0B | 986.2M | 1.1B | 811.7M | |
| Capital Stock | 1.5M | 1.5M | 1.7M | 1.7M | 2.0M | 1.7M | |
| Short Term Debt | 4.7M | 5.5M | 7.3M | 7.3M | 6.5M | 6.3M |
Denali Therapeutics Key Income Statement Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Interest Expense | 15.2M | 17.8M | 13.2M | 14.8M | 17.0M | 8.6M | |
| Total Revenue | 335.7M | 48.7M | 108.5M | 330.5M | 380.1M | 399.1M | |
| Gross Profit | 335.7M | 48.7M | 101.4M | 313.8M | 360.9M | 378.9M | |
| Operating Income | 62.7M | (295.8M) | (340.7M) | (196.7M) | (177.0M) | (185.9M) | |
| Ebit | 62.7M | (295.8M) | (337.4M) | (196.7M) | (177.0M) | (185.9M) | |
| Research Development | 212.6M | 265.4M | 358.7M | 423.9M | 487.5M | 511.8M | |
| Ebitda | 71.2M | (287.2M) | (330.4M) | (180.0M) | (162.0M) | (170.1M) | |
| Cost Of Revenue | 212.6M | 5.6M | 7.0M | 16.7M | 15.1M | 14.3M | |
| Income Before Tax | 72.0M | (291.2M) | (326.0M) | (145.2M) | (130.7M) | (137.2M) | |
| Net Income | 71.1M | (290.6M) | (326.0M) | (145.2M) | (130.7M) | (137.2M) | |
| Income Tax Expense | 823K | (575K) | 21K | 30K | 27K | 25.7K | |
| Net Interest Income | 9.2M | 4.6M | 14.8M | 45.0M | 51.8M | 54.4M | |
| Interest Income | 9.2M | 4.6M | 14.8M | 51.5M | 59.2M | 62.2M | |
| Tax Provision | 823K | (575K) | 21K | (6K) | (5.4K) | (5.7K) |
Denali Therapeutics Key Cash Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Investments | (620.1M) | (13.1M) | (141.4M) | 48.7M | 56.0M | 58.8M | |
| Change In Cash | 427.7M | (213.7M) | (75.4M) | (90.9M) | (81.8M) | (77.7M) | |
| Free Cash Flow | 413.1M | (219.9M) | (262.5M) | (370.9M) | (333.8M) | (317.1M) | |
| Depreciation | 8.5M | 8.6M | 10.4M | 16.7M | 19.2M | 20.2M | |
| Other Non Cash Items | (2.3M) | (3.0M) | (4.9M) | (47.7M) | (42.9M) | (40.8M) | |
| Capital Expenditures | 3.1M | 8.5M | 17.8M | 12.9M | 14.9M | 9.3M | |
| Net Income | 71.1M | (290.6M) | (326.0M) | (145.2M) | (130.7M) | (137.2M) | |
| End Period Cash Flow | 508.6M | 295.0M | 219.5M | 128.7M | 148.0M | 195.6M | |
| Change To Netincome | 38.0M | 50.4M | 91.0M | 94.9M | 109.2M | 114.6M |
Denali Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Denali Therapeutics's current stock value. Our valuation model uses many indicators to compare Denali Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Denali Therapeutics competition to find correlations between indicators driving Denali Therapeutics's intrinsic value. More Info.Denali Therapeutics is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Denali Therapeutics' Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Denali Therapeutics' earnings, one of the primary drivers of an investment's value.Denali Therapeutics Systematic Risk
Denali Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Denali Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty with a total number of output elements of thirty-one. The Beta measures systematic risk based on how returns on Denali Therapeutics correlated with the market. If Beta is less than 0 Denali Therapeutics generally moves in the opposite direction as compared to the market. If Denali Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Denali Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Denali Therapeutics is generally in the same direction as the market. If Beta > 1 Denali Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Denali Therapeutics Thematic Clasifications
Denali Therapeutics is part of Pharmaceutical Products investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions
This theme covers USA Equities from Pharmaceutical Products industry as classified by Fama & French. Fama and French investing themes focus on testing asset pricing under different economic assumptions. Get More Thematic Ideas
| Pharmaceutical Products | View |
Today, most investors in Denali Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Denali Therapeutics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Denali Therapeutics growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Denali Therapeutics January 30, 2025 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Denali Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Denali Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Denali Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Denali Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Denali Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 19.28 | |||
| Value At Risk | (6.79) | |||
| Potential Upside | 6.73 |
Complementary Tools for Denali Stock analysis
When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |